Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group
- PMID: 9596315
- DOI: 10.1378/chest.113.5.1329
Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group
Abstract
Study objective: To study the safety and efficacy of aerosolized recombinant human DNase I in the treatment of idiopathic bronchiectasis.
Design: Double-blind, randomized, placebo-controlled, multicenter study.
Populations: Three hundred forty-nine adult outpatients in stable condition with idiopathic bronchiectasis from 23 centers in North America, Great Britain, and Ireland.
Interventions and measurements: Study patients received aerosolized rhDNase or placebo twice daily for 24 weeks. Primary end points were incidence of pulmonary exacerbations and mean percent change in FEV1 from baseline over the treatment period.
Results: Pulmonary exacerbations were more frequent and FEV1 decline was greater in patients who received rhDNase compared with placebo during this 24-week trial.
Conclusions: rhDNase was ineffective and potentially harmful in this group of adult outpatients in stable condition with idiopathic bronchiectasis. This contrasts with previously published results that demonstrated efficacy of rhDNase in patients with cystic fibrosis bronchiectasis.
Similar articles
-
Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group.N Engl J Med. 1994 Sep 8;331(10):637-42. doi: 10.1056/NEJM199409083311003. N Engl J Med. 1994. PMID: 7503821 Clinical Trial.
-
Short-term recombinant human DNase in bronchiectasis. Effect on clinical state and in vitro sputum transportability.Am J Respir Crit Care Med. 1996 Aug;154(2 Pt 1):413-7. doi: 10.1164/ajrccm.154.2.8756815. Am J Respir Crit Care Med. 1996. PMID: 8756815 Clinical Trial.
-
Aerosolized recombinant human DNase I for the treatment of cystic fibrosis.Chest. 1995 Feb;107(2 Suppl):65S-70S. doi: 10.1378/chest.107.2_supplement.65s. Chest. 1995. PMID: 7842816 Review.
-
Aerosolized recombinant human DNase in hospitalized cystic fibrosis patients with acute pulmonary exacerbations.Am J Respir Crit Care Med. 1996 Jun;153(6 Pt 1):1914-7. doi: 10.1164/ajrccm.153.6.8665055. Am J Respir Crit Care Med. 1996. PMID: 8665055 Clinical Trial.
-
Aerosolized dornase alfa (rhDNase) for therapy of cystic fibrosis.Am J Respir Crit Care Med. 1995 Mar;151(3 Pt 2):S70-4. doi: 10.1164/ajrccm/151.3_Pt_2.S70. Am J Respir Crit Care Med. 1995. PMID: 7881698 Review.
Cited by
-
Bronchiectasis.BMJ Clin Evid. 2015 Feb 25;2015:1507. BMJ Clin Evid. 2015. PMID: 25715965 Free PMC article. Review.
-
Multiple-Breath Washout Outcome Measures in Adults with Bronchiectasis.Ann Am Thorac Soc. 2022 Sep;19(9):1489-1497. doi: 10.1513/AnnalsATS.202006-584OC. Ann Am Thorac Soc. 2022. PMID: 35451922 Free PMC article.
-
Clinimetric Properties of Outcome Measures in Bronchiectasis.Ann Am Thorac Soc. 2023 May;20(5):648-659. doi: 10.1513/AnnalsATS.202206-493OC. Ann Am Thorac Soc. 2023. PMID: 36548542 Free PMC article.
-
Risk of infections in bronchiectasis during disease-modifying treatment and biologics for rheumatic diseases.BMC Infect Dis. 2011 Nov 2;11:304. doi: 10.1186/1471-2334-11-304. BMC Infect Dis. 2011. PMID: 22046967 Free PMC article.
-
Bronchiectasis in Primary Antibody Deficiencies: A Multidisciplinary Approach.Front Immunol. 2020 Mar 31;11:522. doi: 10.3389/fimmu.2020.00522. eCollection 2020. Front Immunol. 2020. PMID: 32296433 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
